Akili, a pioneer in the field of drug medicine, has successfully completed its funding in the amount of $ 55 million. For the C series study in the field of medicine. This funding follows successful testing, including the study, development and testing of a new digital medicine called AKL-T01. This product of Akili's scourging is aimed at treating attention-deficit / hyperactivity disorder (ADHD) type. Once approved and launched commercially, it will be the first digital and autonomous therapeutic medicine for ADHD. AKV-T02 will do other research related to autism spectrum disorder (ASD) or what is simply called autism.
Autism refers to another type of cognitive impairment, especially in children, which makes it difficult for them to interact socially. Repeated behavior and underdevelopment of speech and verbal communication make them vulnerable in society. The cause of autism can be genetic as well as environmental impact.
The above news led to the emergence of a new ray of hope for a patient with autism, where there is no specific traditional medicine for his treatment. This new development has the potential to treat this disorder, perhaps with greater efficiency.
This funding will also help promote products in the pipeline for the treatment of multiple sclerosis (MS) and depression. Once approved by the United States Food and Drug Administration (FDA), it will be commercially launched for patients. According to Akili, AKL-T01 will be the standard treatment for ADHD.
Founder and CEO of the company Eddie Martucci is quite pleased with the response of investors and welcomed the financing. He said that this funding demonstrates people's faith in his company's potential in digital medicine and growth. According to him, the company will continue to grow and provide new solutions in the revised health sector.
Akini Interactive is a company that believes in transforming healthcare through its digital therapy, resolving neurocognitive disorders. He believes in targeting a specific cognitive area or nerve that has been suppressed by dysfunction. Treatment includes, interestingly, not pills, but individual video games for games for patients.
Video games are developed by neurologists and entertainers, developed using algorithms to treat cognitive disorders, such as depression. According to the company, highly interactive and highly attractive games provide therapeutic experience for patients who actually benefit them. Thanks to high-tech interactive video games, specific areas of the brain can become functional, which were suppressed by the disorder, improving the patient's condition. In the second case, monitoring the patient’s cognitive response and the data available for any improvement in the patient’s condition will be second.
AKL-T01, if approved by the FDA, and then it will undoubtedly indicate the adoption of new medical solutions for patients. It can transform the whole process and the health care system in the coming years. This funding will increase the confidence of other investors who plan to invest or get together for research and development in digital medicine in the future, and those patients who are looking for new areas to treat disorders like autism may be more than happy to read such positive news.
